
Journal of the American Chemical Society p. 2177 - 2194 (1991)
Update date:2022-07-30
Topics:
Denmark, Scott E.
Henke, Brad R.
Model compounds 1 and 2 have been studied to elucidate the relative orientation of enolate and carbonyl moieties in the aldol reaction. The syntheses of these compounds have been achieved from a common precursor derived from fragmentation of adamantane. Models of the limiting transition structures reveal that the cyclization must proceed through either a synclinal or antiperiplanar orientation of the aldehyde with respect to the enolate. Cyclizations of 1 were unexpectedly sluggish due to slow deprotonation of the tertiary center. The cyclization of 2 was very rapid and was studied as a function of enolate type (metal counterion), base type, solvent, and additive. The reactions of metal enolates showed an increasing preference for the syn product 5 with increasing cation coordinating ability (K+ < Na+ < Li+ < MgBr+). Attempted cyclization via boron and stannous enolates failed. The type of base and the choice of solvent had negligible effects on the selectivity. However, in the presence of strong cation-complexing agents, the model showed a strong preference for reaction via an antiperiplanar orientation of reactants giving the anti product 6 with high selectivity. The origin of the selectivities and the implication for enolate and transition structures are discussed.
View MoreShanghai shibo Chemical Co., Ltd
Contact:+86-021-60753516
Address:688 Qiushi Road, Jinshan High-tech Park, Shanghai, China,201512
SHIJIAZHUANG HENRYTE CHEMICALS CO,.LTD(expird)
Contact:+86-311-85208698 311-80837698
Address:NO.166, yuhua west road, SHIJIAZHUANG, China
Shaanxi Sinuote Biotech Co.,Ltd
Contact:+86-29-68859685
Address:No 18,Taiyuan Road ,Xi'an city ,China
Kunshan Yalong Trading Co,.Ltd
Contact:86-512-57621185
Address:805-807 Room Hongqiao Mansion ,1088 West Qianjin Road, Kunshan, Jiangsu,China
Shanghai Hohance Chemical Co., ltd
Contact:13914753421
Address:Fl.5;Bld. 70, Lane 1500; Xinfei Road
Doi:10.1016/j.ijpharm.2011.06.007
(2011)Doi:10.1016/0040-4039(95)02130-2
(1996)Doi:10.1002/chem.201103809
(2012)Doi:10.1021/ol301739f
(2012)Doi:10.1002/anie.201201799
(2012)Doi:10.1039/c5sc03704b
(2016)